Phase IV Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol propionate Foam, 0.05% in Adolescent Subjects with Plaque Psoriasis

Main Article Content

Adelaide Hebert
Rhonda Schrieber
Debbie Glaab
Lawrence Eichenfield

Keywords

Psoriasis, Plaque Psoriasis, Topical Steroid, Halobetasol, Adrenal Suppression, Adolescent

Abstract

Abstract not available.

References

1. Bronker et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Pediatr Drugs (2015) 17:373-384

2. Paller et al. Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis. J Drugs Dermatol. 2018;17(2):187-194.

3. Thomas et al. Treating pediatric plaque psoriasis: challenges and solutions. Pediatric Health, Medicine and Therapeutics 2016:7 25-38.

4. Bhatia et al. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects with Plaque Psoriasis. J Drug Dermatol. 2019 Aug 1;18(8):790-796